Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Cancer, Papillary × Mitoxantrone × Endocrine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Iodine-131 6 selpercatinib 5 Magnetic Resonance Spectroscopy 5 Vemurafenib 4 Thyroidectomy 4 lenvatinib 3 dabrafenib 3 Transurethral Resection of Prostate 3 Thyrotropin Alfa 3 Sunitinib 3 vandetanib 2 trametinib 2 entrectinib 2 cobimetinib 2 cabozantinib 2 X-Rays 2 Trastuzumab 2 Thyroid (USP) 2 Surgical Procedures, Operative 2 Specimen Handling 2 Sorafenib 2 Rosiglitazone 2 Radiofrequency Ablation 2 Lymph Node Excision 2 Gefitinib 2 Everolimus 2 Bortezomib 2 AZD 6244 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tremelimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡